Product Launch Tracker: eHCPs are enthusiastic about the first cellular therapy for advanced melanoma.

12.03.2024 | Tracker

Product Launch Tracker: eHCPs are enthusiastic about the first cellular therapy for advanced melanoma.

Every month, CREATION.co’s tracking updates bring you the latest insights from the online conversation of healthcare professionals (eHCPs) across the globe discussing product launches. Discover which new drug approvals eHCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout February 2024 CREATION.co tracked the global conversations of 1,346 eHCPs who posted 1,955 English-language X (formerly Twitter) posts about the launches and approvals of new products.

In February, 160 more eHCPs discussed treatment approvals compared to January and there were 19% more eHCP mentions of new pharmaceutical product launches and drug approvals.

On 16 February, the FDA approved Iovance Biotherapeutics’ Amtagvi (lifileucel), the first cellular therapy to treat patients with unresectable or metastatic melanoma. eHCPs were thrilled about the approval, calling it a “major milestone” and a “genuine game changer” in the solid tumour therapy area. Tens of eHCPs, including Dr Ian Weissman, characterised the treatment as groundbreaking, as it shrank tumours in a third of the patients who had run out of treatments. Among other eHCPs, Dr Patrick Hanley congratulated the team behind this medical advancement.

On the same day, the FDA approved AstraZeneca’s Tagrisso (osimertinib) combined with chemotherapy for patients with EGFR-mutated non-small cell lung cancer.

A few eHCPs took into account some of the advantages that the treatment can offer, such as significant progression-free survival benefits. However, more eHCPs were critical of the approval stating that “the FDA has no standards” and that “they are permitting an option that could worsen outcomes for people”. This negative sentiment was also present because overall survival data were considered not mature enough and physicians suggested the treatment had an unclear impact on survival

Dr Estela Rodruguez expressed her opinion stating that sometimes the FDA approves treatments that as a doctor, she is not ready to start in all patients”. 

Also on 16 February, the FDA approved Genentech’s Xolair (omalizumab) injection as the first medication to help reduce allergic reactions to multiple foods after accidental exposure. eHCPs were thrilled about this approval and characterised it as a “very exciting announcement”. Dr Jual Ivancevich posted online stating that “this groundbreaking approval provides new hope for those affected”. eHCPs also congratulated the team who contributed to creating this treatment.

The three most shared stories from eHCPs discussing product launches in February were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint® the English-language X conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 February and 29 February 2024 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their X conversations.
  • Between 1 February and 29 February 2024, there were 1,346 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,955 unique eHCP authors from around the world. 

 

Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


10.06.2021 | Article

5 Lessons from the impact of congress going virtual on HCP conversations

Virtual oncology congresses fair well in COVID-focused year

By Jamie Doggett

Top 50 Pharma Tracker: HCPs respond to Pharma Covid-19 activity

05.05.2020 | Article

Top 50 Pharma Tracker: HCPs respond to Pharma Covid-19 activity

Top 50 Pharma Tracker: HCPs respond to Pharma Covid-19 activity

By Mary Kangley

View all articles >